{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:56:14Z","timestamp":1649152574187},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.diagmicrobio.2013.11.003","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T17:48:14Z","timestamp":1384451294000},"page":"168-171","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection"],"prefix":"10.1016","volume":"78","author":[{"given":"Yoshiko","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Mitsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0010","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.41.10.2256","article-title":"Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses","volume":"41","author":"Chein","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1469-0691.2006.01395.x","article-title":"Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia","volume":"12","author":"File","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0020","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3201\/eid1408.070751","article-title":"Bacterial pneumonia and pandemic influenza planning","volume":"14","author":"Gupta","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2011.06.046","article-title":"Anti\u2013inflammatory effects of garenoxacin on IL\u20138 production and ERK1\/2 activation induced by lipopolysaccharides in A549 and THP-1 cells","volume":"668","author":"Hara","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0030","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/AAC.50.2.748-751.2006","article-title":"Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice","volume":"50","author":"Hayashi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/596051","article-title":"Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza","volume":"199","author":"Karlstr\u00f6m","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0040","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/421525","article-title":"Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza","volume":"190","author":"McCullers","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/CMR.00058-05","article-title":"Insights into the interaction between influenza virus and pneumococcus","volume":"19","author":"McCullers","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0050","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1086\/591708","article-title":"Predominant role of bacterial pneumonia as cause of death in pandemic influenza: implications for pandemic influenza preparedness","volume":"198","author":"Morens","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2008.06.032","article-title":"Clinical studies of garenoxacin","volume":"32","author":"Takagi","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10156-012-0434-3","volume":"18","author":"Watanabe","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/49.1.177","article-title":"The in vitro activity of BMS-284756, a new des-fluorinated quinolone","volume":"49","author":"Weller","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2009.05.006","article-title":"Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates","volume":"65","author":"Yokota","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.003_bb0075","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.47.11.3548-3553.2003","article-title":"Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis","volume":"47","author":"Zeitlinger","year":"2003","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T21:46:30Z","timestamp":1564695990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889313005889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0732889313005889"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.11.003","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}